Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.60 |
| ▸ | TYK2 | P29597 | 16/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12295360 | 0.88 | JAK2 (0.60) | JAK2TYK2PTGES | |
| SCHEMBL14858365 | 0.88 | JAK2 (0.47) | JAK2TYK2PTGES | |
| SCHEMBL2383138 | 0.84 | JAK2 (0.56) | JAK2TYK2JAK1CCNA2CDK2 | |
| SCHEMBL2371815 | 0.83 | TYK2 (0.53) | JAK2TYK2JAK1PTGESCCNA2 | |
| SCHEMBL2372938 | 0.79 | TYK2 (0.59) | JAK2TYK2JAK1CDK2KDR | |
| SCHEMBL2371810 | 0.78 | JAK2 (0.48) | JAK2TYK2KDR | |
| SCHEMBL2371216 | 0.78 | TYK2 (0.70) | JAK2TYK2JAK1CDK2KDR | |
| SCHEMBL2372898 | 0.78 | TYK2 (0.72) | JAK2TYK2JAK1CDK2KDR | |
| SCHEMBL2372568 | 0.77 | TYK2 (0.48) | JAK2TYK2JAK1KDR | |
| SCHEMBL2372465 | 0.77 | TYK2 (0.69) | JAK2TYK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | JAK2 6/4885TYK2 1/4885JAK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.